Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. - Wikidata - thesis-toulmin - TriplyDB

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

http://www.wikidata.org/entity/Q43169904

about

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections Antimicrobial Peptides Targeting Gram-Positive Bacteria Management of multidrug-resistant enterococcal infections A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections Host-guest chemistry of the peptidoglycan Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.N-terminally modified linear and branched spermine backbone dipeptidomimetics against planktonic and sessile methicillin-resistant Staphylococcus aureus.Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections Antimicrobial properties of 8-hydroxyserrulat-14-en-19-oic acid for treatment of implant-associated infections.The membrane as a target for controlling hypervirulent Clostridium difficile infections.The cell wall architecture of Enterococcus faecium: from resistance to pathogenesis.New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections.Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.Oritavancin: A Long-Half-Life Lipoglycopeptide.Oritavancin: a review in acute bacterial skin and skin structure infections.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Oritavancin: a long-acting antibacterial lipoglycopeptide.Targeting bactoprenol-coupled cell envelope precursors.Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections.Activity of short lipopeptides and conventional antimicrobials against planktonic cells and biofilms formed by clinical strains of Staphylococcus aureus.In vitro activities of dermaseptins K4S4 and K4K20S4 against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa planktonic growth and biofilm formation.Comparing the action of HT61 and chlorhexidine on natural and model Staphylococcus aureus membranes.Orthopaedic biofilm infections.Evaluation of Antibiotics Active against Methicillin-Resistant Staphylococcus aureus Based on Activity in an Established Biofilm Characterizing the transcriptional adaptation of Staphylococcus aureus to stationary phase growth.Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.Pseudomonas aeruginosa exopolysaccharide Psl promotes resistance to the biofilm inhibitor polysorbate 80.Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci.Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity Effective antimicrobial activity of Cbf-K16 and Cbf-A7 A13 against NDM-1-carrying Escherichia coli by DNA binding after penetrating the cytoplasmic membrane in vitro.Graft copolymer polyelectrolyte complexes for delivery of cationic antimicrobial peptides.Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin.Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria.

P2860

Q24606291-2C294F4E-EED7-4460-8247-95D6E03801C3 Q26772897-C390040A-62A6-447C-802E-8E6081B6CCB7 Q26799701-91ED78FF-0E8C-4624-9C98-6B9B81F37095 Q28077888-D813769A-D542-4801-91EB-D588785A75DB Q28285907-56C64814-7B1F-4A35-B4E0-8F66D6975223 Q28474929-27173470-B2C4-4A5A-9463-863668FC1243 Q34013593-540ACD7E-03ED-4864-A7D6-66D93A664BDB Q35065786-F1C44E60-0484-428C-B176-8D99DBC3FB22 Q35198896-A2924E62-FEA5-4C45-85C7-A04F9FAAFAD5 Q36393640-F81D1A88-C46F-489F-9978-D54A5CB53AF0 Q36505571-146F2634-FAE2-470C-9E5E-5A1B7BBC9523 Q36963920-873AC93E-832D-4081-9213-B9C540D31AC2 Q38125495-4C62B777-5B63-4DC4-B951-200DE1C36FC1 Q38179460-3F449524-665C-4BB6-ACC7-41D92D530B6F Q38233471-B22A2AB4-93BA-47B2-8FB8-7B49AC2C4A63 Q38347869-076A367C-64EA-40BD-B0A0-7789FD9BFAB0 Q38364691-D9DAB5DE-ECE6-44AD-8204-E5EC12CA9181 Q38434265-AB9A077C-3AA7-4D3B-94D4-9C1A685C5495 Q38606618-15DA5550-54B2-469A-AF72-2D60379425A8 Q38615330-09B91379-08A4-4258-9272-733CFCF40E2D Q38646905-5E3D5FC7-1539-4FEC-A424-DAB987DAAEE6 Q38830176-8483CD6B-BFF9-433F-B1E3-C61D8B84DF62 Q38919751-AACAE1BA-1599-46DD-97D5-C9C2DCFE899A Q39352419-BF12513B-3776-4D47-858F-225428F75FD3 Q39564554-D908061B-AB92-4636-ADDD-4CD92FF0DCEC Q39684214-38990912-8805-4AB4-B811-D8555BCCA228 Q40110502-113A4D58-2198-47D4-A68F-FDF3438A8B5B Q40252041-DA90031F-8F77-426F-8374-C2B3095FBEA6 Q40617957-9CFFB755-A1AE-48FE-AD52-8F738ED578E4 Q40681057-244147B8-E79C-4133-A180-725A4516B753 Q40719299-DB30142B-19F0-48AF-9338-3E1E6A831624 Q42097620-E36C3F0C-C543-4DAF-AA68-292BEC4834E7 Q42111507-1399839B-BE80-4961-B61D-46F0ACBCA9E0 Q42231593-574C2018-466B-4C2C-883F-2939757725E0 Q42530056-ECF75DF7-D1F4-4BDD-A673-EDF08499858C Q42696736-04AA25B3-A507-4865-9F2F-465EB6CF33D0 Q43445362-3AA3DF49-2A70-4F47-B92A-9D02AE838F6A Q43574112-73AEDD6A-E5F0-4D04-A40B-BBE75083EFFD Q45059895-3C82C524-431B-40BE-A49B-E7D1810288A9 Q47236751-06996D4B-D864-4623-ABB6-33C7A2203AFC

P2860

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

http://www.wikidata.org/entity/Q43169904

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

@en

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

@nl

type

label

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

@en

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

@nl

prefLabel

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

@en

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

@nl

P1433

Q43169904-672824C1-B049-41E1-9CE6-80D5FD913379

P1476

Q43169904-62986301-558F-4990-9C94-281B975233B9

P2093

Q43169904-175EFDAA-A04F-4B45-B89E-5E1CBBE9473C

Q43169904-5328E4E7-A964-4823-AE46-4D0109454062

Q43169904-7BF84803-0993-4026-9915-3380BEAA94FA

Q43169904-99036C3D-4027-43FA-84F7-F1155014BD3C

Q43169904-D18480D1-EBB9-4210-8AEB-813DC45036B1

Q43169904-DE1708F1-DBA6-4966-B3A3-DF1F47ED9150

Q43169904-FA988324-7249-4572-BBC4-E247BB78CFBF

P2860

Q43169904-06BA1FA0-9A9B-45E7-B1D8-1596DC63ACBD

Q43169904-10FB4FCF-1349-4AB9-B62B-F60E4AA78965

Q43169904-19ABCFF3-E094-4D00-AA8D-D50F661B2D45

Q43169904-1BFF6926-FCF1-47C8-B3BE-FF485890D473

Q43169904-24C1BB6E-5926-4218-AD4F-65A9D3ACEFA2

Q43169904-394DFA3D-19CE-42CD-B5D4-EAE007395D60

Q43169904-3A3D1723-5E26-45F4-91DA-C94C6681EBC4

Q43169904-3E028628-8C8D-44EE-8088-258B662B5114

Q43169904-41304767-4186-466D-85D2-8877B9F68923

Q43169904-501C3DC4-914F-4B12-8D03-49A735EB8B40

P304

Q43169904-C05F93A3-3E37-4BF2-B817-FA4FBA2726A7

P31

Q43169904-5A698F85-68CA-48E1-B659-5257E72DDA17

P356

Q43169904-23D6C581-F0C8-490E-85E3-473631E3C94C

P407

Q43169904-7D7FD23C-84A3-4C71-B4D6-E46EF8CFE6A5

P433

Q43169904-CDB31EF6-483B-4A05-8241-E65BF6F754DB

P478

Q43169904-78A9566F-E798-42ED-A21A-08C584C45E80

P50

Q43169904-497F365E-03A1-486D-87EF-294396EDF349

P577

Q43169904-FF60A6CE-E244-49B2-AAFF-02E21B003043

P698

Q43169904-A38EA634-4094-4B0E-8CB7-CA684741CA08

P921

Q43169904-F043D8CE-42A1-48B4-8F07-A28D31DC3F37

P932

Q43169904-49B13C0A-357F-4B11-B4DE-08863E9AADF2

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro

@en

P2093

Adam Belley

http://www.w3.org/2001/XMLSchema#string

Eve Neesham-Grenon

http://www.w3.org/2001/XMLSchema#string

Francis F Arhin

http://www.w3.org/2001/XMLSchema#string

Geoffrey McKay

http://www.w3.org/2001/XMLSchema#string

Robert Harris

http://www.w3.org/2001/XMLSchema#string

Terry Beveridge

http://www.w3.org/2001/XMLSchema#string

Thomas R Parr

http://www.w3.org/2001/XMLSchema#string

P2860

Biofilms: survival mechanisms of clinically relevant microorganisms.

Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells

In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci

Bacterial biofilms: a common cause of persistent infections

Persister cells, dormancy and infectious disease

Spatial patterns of DNA replication, protein synthesis, and oxygen concentration within bacterial biofilms reveal diverse physiological states.

Physiological heterogeneity in biofilms.

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.

P304

918-925

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00766-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19104027

http://www.w3.org/2001/XMLSchema#string

P921

P932

2650528

http://www.w3.org/2001/XMLSchema#string